Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The FDA has signed off Compass Therapeutics Inc's (NASDAQ:CMPX) IND application for CTX-009 to initiate a global Phase 2 clinical trial for CTX-009 for advanced Biliary Tract Cancers (BTC) in the U.S. and South Korea.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- The Company plans to include the existing Phase 2 in South Korea in this global study, allowing it to expand the ongoing study of CTX-009 under this IND.
- CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A).
- The Phase 2a trial in South Korea is testing CTX-009 combined with paclitaxel in BTC patients.
- The Company said that five partial responses have already been observed among the first 17 patients evaluated, leading to a preliminary overall response rate (ORR) of 29%.
- All patients evaluated have had stable disease or better, with a decline in tumor burden observed in 16 of the 17 patients leading to a Clinical Benefit Rate of 100%.
- Price Action: CMPX shares are down 1.06% at $2.80 during the market session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.